A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
Identifieur interne : 002150 ( PubMed/Curation ); précédent : 002149; suivant : 002151A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
Auteurs : Tarik Asselah [France] ; Alex J. Thompson [Australie] ; Robert Flisiak [Pologne] ; Manuel Romero-Gomez [Espagne] ; Diethelm Messinger [Allemagne] ; Georgios Bakalos [Suisse] ; Mitchell L. Shiffman [États-Unis]Source :
- PloS one [ 1932-6203 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Charge virale, Femelle, Génotype, Hepacivirus (génétique), Humains, Hépatite C chronique (traitement médicamenteux), Hépatite C chronique (virologie), Interféron alpha (administration et posologie), Interféron alpha (usage thérapeutique), Jeune adulte, Modèles théoriques, Mâle, Polyéthylène glycols (administration et posologie), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (administration et posologie), Protéines recombinantes (usage thérapeutique), Ribavirine (administration et posologie), Ribavirine (usage thérapeutique), Sujet âgé, Études rétrospectives.
- MESH :
- administration et posologie : Antiviraux, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- génétique : Hepacivirus.
- traitement médicamenteux : Hépatite C chronique.
- usage thérapeutique : Antiviraux, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- virologie : Hépatite C chronique.
- Adolescent, Adulte, Adulte d'âge moyen, Charge virale, Femelle, Génotype, Humains, Jeune adulte, Modèles théoriques, Mâle, Sujet âgé, Études rétrospectives.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Female, Genotype, Hepacivirus (genetics), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (virology), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (therapeutic use), Male, Middle Aged, Models, Theoretical, Polyethylene Glycols (administration & dosage), Polyethylene Glycols (therapeutic use), Recombinant Proteins (administration & dosage), Recombinant Proteins (therapeutic use), Retrospective Studies, Ribavirin (administration & dosage), Ribavirin (therapeutic use), Viral Load, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- drug therapy : Hepatitis C, Chronic.
- genetics : Hepacivirus.
- virology : Hepatitis C, Chronic.
- Adolescent, Adult, Aged, Female, Genotype, Humans, Male, Middle Aged, Models, Theoretical, Retrospective Studies, Viral Load, Young Adult.
Abstract
Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy.
DOI: 10.1371/journal.pone.0150569
PubMed: 26991780
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002176
Links to Exploration step
pubmed:26991780Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.</title><author><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche sur l'Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d'Hépatologie, AP-HP Hôpital Beaujon, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche sur l'Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d'Hépatologie, AP-HP Hôpital Beaujon, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Thompson, Alex J" sort="Thompson, Alex J" uniqKey="Thompson A" first="Alex J" last="Thompson">Alex J. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC</wicri:regionArea></affiliation></author><author><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540, Białystok, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540, Białystok</wicri:regionArea></affiliation></author><author><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name><affiliation wicri:level="1"><nlm:affiliation>UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville</wicri:regionArea></affiliation></author><author><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name><affiliation wicri:level="1"><nlm:affiliation>Biostatistics, PROMETRIS GmbH, 68219, Mannheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Biostatistics, PROMETRIS GmbH, 68219, Mannheim</wicri:regionArea></affiliation></author><author><name sortKey="Bakalos, Georgios" sort="Bakalos, Georgios" uniqKey="Bakalos G" first="Georgios" last="Bakalos">Georgios Bakalos</name><affiliation wicri:level="1"><nlm:affiliation>Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel</wicri:regionArea></affiliation></author><author><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L" last="Shiffman">Mitchell L. Shiffman</name><affiliation wicri:level="1"><nlm:affiliation>Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26991780</idno><idno type="pmid">26991780</idno><idno type="doi">10.1371/journal.pone.0150569</idno><idno type="wicri:Area/PubMed/Corpus">002176</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002176</idno><idno type="wicri:Area/PubMed/Curation">002150</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002150</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.</title><author><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche sur l'Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d'Hépatologie, AP-HP Hôpital Beaujon, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche sur l'Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d'Hépatologie, AP-HP Hôpital Beaujon, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Thompson, Alex J" sort="Thompson, Alex J" uniqKey="Thompson A" first="Alex J" last="Thompson">Alex J. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC</wicri:regionArea></affiliation></author><author><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540, Białystok, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540, Białystok</wicri:regionArea></affiliation></author><author><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name><affiliation wicri:level="1"><nlm:affiliation>UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville</wicri:regionArea></affiliation></author><author><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name><affiliation wicri:level="1"><nlm:affiliation>Biostatistics, PROMETRIS GmbH, 68219, Mannheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Biostatistics, PROMETRIS GmbH, 68219, Mannheim</wicri:regionArea></affiliation></author><author><name sortKey="Bakalos, Georgios" sort="Bakalos, Georgios" uniqKey="Bakalos G" first="Georgios" last="Bakalos">Georgios Bakalos</name><affiliation wicri:level="1"><nlm:affiliation>Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel</wicri:regionArea></affiliation></author><author><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L" last="Shiffman">Mitchell L. Shiffman</name><affiliation wicri:level="1"><nlm:affiliation>Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA</wicri:regionArea></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Female</term><term>Genotype</term><term>Hepacivirus (genetics)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Hepatitis C, Chronic (virology)</term><term>Humans</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Models, Theoretical</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (therapeutic use)</term><term>Retrospective Studies</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (therapeutic use)</term><term>Viral Load</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Charge virale</term><term>Femelle</term><term>Génotype</term><term>Hepacivirus (génétique)</term><term>Humains</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Hépatite C chronique (virologie)</term><term>Interféron alpha (administration et posologie)</term><term>Interféron alpha (usage thérapeutique)</term><term>Jeune adulte</term><term>Modèles théoriques</term><term>Mâle</term><term>Polyéthylène glycols (administration et posologie)</term><term>Polyéthylène glycols (usage thérapeutique)</term><term>Protéines recombinantes (administration et posologie)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Ribavirine (administration et posologie)</term><term>Ribavirine (usage thérapeutique)</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Models, Theoretical</term><term>Retrospective Studies</term><term>Viral Load</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Femelle</term><term>Génotype</term><term>Humains</term><term>Jeune adulte</term><term>Modèles théoriques</term><term>Mâle</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26991780</PMID><DateCreated><Year>2016</Year><Month>03</Month><Day>19</Day></DateCreated><DateCompleted><Year>2016</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.</ArticleTitle><Pagination><MedlinePgn>e0150569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0150569</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The score was validated using a database of 473 patients. Scores were assigned for six factors as follows: age (years) (≤40: 2 points; >40 but ≤55: 1); bodyweight (kg) (<70: 2; ≥70 but <90: 1); no cirrhosis/transition to cirrhosis (2); ALT ≤2.5 x ULN (1); platelets (109/L) (>200: 2; ≥100 but <200: 1); HCV RNA (<400,000 IU/mL: 1). The points are summed to arrive at a score ranging from 0‒10 where higher scores indicate higher chances of SVR; 141, 123, 203, 249, 232, and 218 patients had total scores of 0‒4, 5, 6, 7, 8, and 9-10, respectively, among whom SVR rates were 45%, 62%, 72%, 76%, 84%, and 89%. Among 622 patients who had scores of 6‒10 and HCV RNA <50 IU/mL by treatment week 4 the SVR rate was 86% (532/622).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A simple baseline scoring system involving age, bodyweight, cirrhosis status, ALT level, platelet count and HCV RNA level can be used to identify treatment-naive Caucasian patients with HCV GT3 infection with a high probability of SVR with PegIFN alfa-2a/RBV therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asselah</LastName><ForeName>Tarik</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre de Recherche sur l'Inflammation (CRI), UMR 1149 Inserm, Université Paris Diderot, Service d'Hépatologie, AP-HP Hôpital Beaujon, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alex J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flisiak</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540, Białystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Gomez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UCM Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messinger</LastName><ForeName>Diethelm</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biostatistics, PROMETRIS GmbH, 68219, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakalos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiffman</LastName><ForeName>Mitchell L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Studies</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q46947FE7K</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(6):e99126</RefSource><PMID Version="1">24914551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2011 Oct;18(10):e516-22</RefSource><PMID Version="1">21914071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2004 Dec;40(6):1260-5</RefSource><PMID Version="1">15558712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2004 Mar 2;140(5):346-55</RefSource><PMID Version="1">14996676</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(10):e108751</RefSource><PMID Version="1">25302676</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2009;14(2):143-54</RefSource><PMID Version="1">19430089</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jan 16;370(3):211-21</RefSource><PMID Version="1">24428467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2015 Jul;63(1):199-236</RefSource><PMID Version="1">25911336</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Gastroenterol Hepatol. 2011 Apr;9(4):344-350.e2</RefSource><PMID Version="1">20728570</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2014 Nov;34(10):1550-9</RefSource><PMID Version="1">24329937</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterol Hepatol (N Y). 2015 Jun;11(6 Suppl 3):1-23</RefSource><PMID Version="1">26504459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2009 Oct;51(4):655-66</RefSource><PMID Version="1">19665246</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2011 Mar;53(3):746-54</RefSource><PMID Version="1">21374656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 May 15;370(20):1869-71</RefSource><PMID Version="1">24720680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gut. 2007 Apr;56(4):553-9</RefSource><PMID Version="1">16956917</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 May 22;370(21):1993-2001</RefSource><PMID Version="1">24795201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2014 Feb;34 Suppl 1:69-78</RefSource><PMID Version="1">24373081</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2015 Sep;62(3):932-54</RefSource><PMID Version="1">26111063</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Dec 31;373(27):2678-80</RefSource><PMID Version="1">26575359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jul 12;357(2):124-34</RefSource><PMID Version="1">17625124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2008 Jun;47(6):1837-45</RefSource><PMID Version="1">18454508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2008 Jan;47(1):35-42</RefSource><PMID Version="1">17975791</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Jun 23;352(25):2609-17</RefSource><PMID Version="1">15972867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2014 Apr;39(7):686-98</RefSource><PMID Version="1">24612116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2005 Aug;129(2):522-7</RefSource><PMID Version="1">16083709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2009 Sep 17;461(7262):399-401</RefSource><PMID Version="1">19684573</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2004 May 30;23(10):1631-60</RefSource><PMID Version="1">15122742</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2010 Jun;51(6):1897-903</RefSource><PMID Version="1">20196118</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</RefSource><PMID Version="1">25086286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2012 Dec;56(6):2039-50</RefSource><PMID Version="1">22706730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2013 Apr;57(4):1333-42</RefSource><PMID Version="1">23172780</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4798721</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26991780</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0150569</ArticleId><ArticleId IdType="pii">PONE-D-15-40146</ArticleId><ArticleId IdType="pmc">PMC4798721</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002150 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002150 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26991780
|texte= A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26991780" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |